...to date. Eli Lilly and Co. (NYSE:LLY) gains exclusive, worldwide rights to four targets from Sitryx Therapeutics Ltd....
...outbreak. Targets IL17A - Interleukin-17A JAK-1 - Janus kinase-1 JAK-2 - Janus kinase-2 Paul Bonanos, Associate Editor Sitryx Therapeutics Ltd. Eli...

...solid tumors. This makes sense in autoimmunity, according to Paul-Peter Tak, co-founder of immuno-metabolism company Sitryx Therapeutics Ltd....
...Co. Inc. (NYSE:MRK), Kenilworth, N.J. Pfizer Inc. (NYSE:PFE), New York, N.Y. Scipher Medicine, Boston, Mass. Sitryx Therapeutics Ltd....

...Tak, former chief immunology officer and SVP R&D pipeline at GSK. Tak is co-founder of Sitryx Therapeutics Ltd....
...of America (PhRMA), Washington, D.C. Roche (SIX:ROG; OTCQX:RHHBY), Basel, Switzerland Sanofi (NYSE:SNY; Euronext:SAN), Paris, France Sitryx Therapeutics Ltd....

...With a $30 million series A round and a pipeline of immunometabolism programs, Sitryx Therapeutics Ltd. became the...

...Weir declined to disclose whether the series A round is tranched. Sitryx Therapeutics Ltd., Oxford, U.K. Allison Johnson GlaxoSmithKline plc Sitryx Therapeutics Ltd. SV...

...to disclose whether the series A round is tranched. Allison Johnson GlaxoSmithKline plc SV Health Investors Immunology Network immunometabolism Neil Weir Paul-Peter Tak Sitryx Therapeutics Ltd....